
DHR · NYSE
Danaher Corporation
$230.50 +0.79 (+0.34%)
Company overview
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization, microscopes, genomics consumables, and gene and cell therapy offerings, as well as bioprocess technologies, consumables, services, and filtration, separation, and purification technologies to pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools, research institutions, and various industrial manufacturers.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Exchange
- NYSE
- Market cap
- $162B
- Employees
- 61,000
- Headquarters
- Washington, DC
- Website
- danaher.com
- CEO
- Rainer Blair
- Listed
- December 29, 1978
- P/E
- 44.41
- Dividend yield
- 0.69%
Company financials
- Revenue
- $24.8B
- Gross profit
- $15B
- Operating income
- $5.2B
- EBITDA
- $6.7B
- Net income
- $3.7B
- EPS
- $5.19
- Total assets
- $83.5B
- Total debt
- $18.5B
- Gross margin
- 60.68%
- Net margin
- 14.89%
- Earnings yield
- 2.25%
Showing FY 2025